<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882661</url>
  </required_header>
  <id_info>
    <org_study_id>GPR002</org_study_id>
    <nct_id>NCT00882661</nct_id>
  </id_info>
  <brief_title>SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study</brief_title>
  <official_title>A Prospective Randomized Clinical Investigation of the SECURE-C Cervical Artificial Disc: A Pivotal Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Globus Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Globus Medical Inc</source>
  <brief_summary>
    <textblock>
      The purpose of the pivotal IDE clinical study was to evaluate the safety and effectiveness of
      the SECURE®-C Cervical Artificial Disc for the treatment of symptomatic cervical disc disease
      at one level between C3 and C7, compared to anterior cervical discectomy and fusion.

      The purpose of the Postmarket Approval Study is to evaluate the long-term safety and efficacy
      associated with the use of the SECURE-C Cervical Artificial Disc
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ages Eligible for Study: 18 to 60 years

      Genders Eligible for Study: Both

      Accepts Healthy Volunteers: No
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual Patient Overall Success</measure>
    <time_frame>24 months</time_frame>
    <description>Individual patient overall success defined as pain/disability improvement of at least 25% in Neck Disability Index (NDI) compared to baseline; no device failures requiring revision, removal, reoperation, or supplemental fixation; absence of major complications defined as major vessel injury, neurological damage, or nerve injury; and for control fusion patients only, radiographic fusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neck Disability Index (NDI)</measure>
    <time_frame>24 months</time_frame>
    <description>Neck Disability Index (NDI) success defined as ≥25% improvement at 24 months from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck Pain Visual Analog Scale (VAS)</measure>
    <time_frame>24 months</time_frame>
    <description>Improvement of 20mm from baseline in neck pain measured using the Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Arm Pain Visual Analog Scale (VAS)</measure>
    <time_frame>24 months</time_frame>
    <description>Improvement of 20mm from baseline in left arm pain measured using the Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Arm Pain Visual Analog Scale (VAS)</measure>
    <time_frame>24 months</time_frame>
    <description>Improvement of 20mm from baseline in right arm pain measured using the Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 PCS</measure>
    <time_frame>24 months</time_frame>
    <description>Health Status Survey SF-36 physical composite scores: 15% improvement from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 MCS</measure>
    <time_frame>24 months</time_frame>
    <description>Health Status Survey SF-36 mental composite scores: 15% improvement from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>24 months</time_frame>
    <description>Patient satisfaction (definitely/mostly): proportion of patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Symptomatic Cervical Disc Disease</condition>
  <arm_group>
    <arm_group_label>SECURE-C Cervical Artificial Disc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASSURE Cervical plate and an allograft interbody spacer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SECURE-C Cervical Artificial Disc</intervention_name>
    <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
    <arm_group_label>SECURE-C Cervical Artificial Disc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ASSURE Cervical plate and an allograft interbody spacer</intervention_name>
    <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
    <arm_group_label>ASSURE Cervical plate and an allograft interbody spacer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic cervical disc disease (SCDD) in one vertebral level between C3-C7, defined
             as neck or arm (radicular) pain, or functional or neurological deficit and
             radiographic confirmation (by CT, MRI, X-ray, etc.) of any of the following:

          -  Herniated nucleus pulposus;

          -  Radiculopathy or myelopathy;

          -  Spondylosis (defined by the presence of osteophytes); or

          -  Loss of disc height.

          -  Age between 18 and 60 years

          -  Failed at least 6 weeks of conservative treatment

          -  Neck Disability Index (NDI) Questionnaire score of at least 30 (as percentage of 50
             point total)

          -  Able to understand and sign informed consent form

          -  Psychosocially, mentally and physically able to fully comply with this protocol
             including adhering to follow-up schedule and filling out forms

          -  Able to meet the proposed follow-up schedule at 6 weeks, 3 months, 6 months, 12 months
             and 24 months

          -  Able to follow postoperative management program

        Exclusion Criteria:

          -  More than one vertebral level requiring treatment

          -  Prior fusion surgery adjacent to the vertebral level being treated

          -  Prior surgery at the level to be treated

          -  Clinically compromised vertebral bodies at the affected level(s) due to current or
             past trauma

          -  Radiographic confirmation of facet joint disease or degeneration, defined as apparent
             sclerosis and/or hypertrophy of the facets demonstrated on AP radiographs as a
             disruption of the normally smooth facet curve

          -  Marked cervical instability on resting lateral or flexion/extension radiographs:

          -  Translation greater than 3mm, and/or

          -  More than 11° of rotational difference from that of either adjacent level.

          -  Severe spondylosis at the level to be treated as characterized by any of the
             following:

          -  Bridging osteophytes;

          -  A loss of disc height greater than 50%; or

          -  Absence of motion (&lt;2°)

          -  Neck or arm pain of unknown etiology

          -  Osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone
             disease

          -  Pregnant or interested in becoming pregnant in the next 2 years

          -  Active systemic or local infection

          -  Known allergy to titanium, polyethylene, cobalt, chromium or molybdenum

          -  Taking medications or any drug known to potentially interfere with bone/soft tissue
             healing (e.g., steroids)

          -  Rheumatoid arthritis or other autoimmune disease

          -  Systemic disease including AIDS, HIV, Hepatitis

          -  Active malignancy: A patient with a history of any invasive malignancy (except
             non-melanoma skin cancer), unless he/she has been treated with curative intent and
             there has been no clinical signs or symptoms of the malignancy for at least 5 years

          -  Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy,
             amyotrophic lateral sclerosis, etc.

          -  Acute mental illness or substance abuse

          -  Use of bone growth stimulator within past 30 days

          -  Participation in other investigational device or drug clinical trials within 30 days
             of surgery

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph M Marzluff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trident Regional Medical Center</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <results_first_submitted>August 21, 2014</results_first_submitted>
  <results_first_submitted_qc>June 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2017</results_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neck Pain</keyword>
  <keyword>Arm Pain</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SECURE-C Cervical Artificial Disc</title>
          <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
        </group>
        <group group_id="P2">
          <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
          <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Investigational Training</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized SECURE-C Cervical Artificial Disc</title>
          <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
        </group>
        <group group_id="B2">
          <title>ASSURE Cervical Plate and Allograft Interbody Spacer</title>
          <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
        </group>
        <group group_id="B3">
          <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
          <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="380"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="7.5"/>
                    <measurement group_id="B2" value="44.4" spread="7.9"/>
                    <measurement group_id="B3" value="41.6" spread="8.13"/>
                    <measurement group_id="B4" value="43.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Individual Patient Overall Success</title>
        <description>Individual patient overall success defined as pain/disability improvement of at least 25% in Neck Disability Index (NDI) compared to baseline; no device failures requiring revision, removal, reoperation, or supplemental fixation; absence of major complications defined as major vessel injury, neurological damage, or nerve injury; and for control fusion patients only, radiographic fusion</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete primary endpoint data was available for 79 Non-randomized SECURE-C patients,141 randomized SECURE-C patients and 114 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Patient Overall Success</title>
          <description>Individual patient overall success defined as pain/disability improvement of at least 25% in Neck Disability Index (NDI) compared to baseline; no device failures requiring revision, removal, reoperation, or supplemental fixation; absence of major complications defined as major vessel injury, neurological damage, or nerve injury; and for control fusion patients only, radiographic fusion</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete primary endpoint data was available for 79 Non-randomized SECURE-C patients,141 randomized SECURE-C patients and 114 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neck Disability Index (NDI)</title>
        <description>Neck Disability Index (NDI) success defined as ≥25% improvement at 24 months from baseline</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Neck Disability Index (NDI) data was available for 78 Non-randomized SECURE-C patients,139 randomized SECURE-C patients and 116 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc</description>
          </group>
        </group_list>
        <measure>
          <title>Neck Disability Index (NDI)</title>
          <description>Neck Disability Index (NDI) success defined as ≥25% improvement at 24 months from baseline</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Neck Disability Index (NDI) data was available for 78 Non-randomized SECURE-C patients,139 randomized SECURE-C patients and 116 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neck Pain Visual Analog Scale (VAS)</title>
        <description>Improvement of 20mm from baseline in neck pain measured using the Visual Analog Scale (VAS)</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Neck Pain Visual Analog Scale (VAS) data was available for 75 non-randomized SECURE-C, 133 randomized SECURE-C patients and 108 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc</description>
          </group>
        </group_list>
        <measure>
          <title>Neck Pain Visual Analog Scale (VAS)</title>
          <description>Improvement of 20mm from baseline in neck pain measured using the Visual Analog Scale (VAS)</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Neck Pain Visual Analog Scale (VAS) data was available for 75 non-randomized SECURE-C, 133 randomized SECURE-C patients and 108 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Arm Pain Visual Analog Scale (VAS)</title>
        <description>Improvement of 20mm from baseline in left arm pain measured using the Visual Analog Scale (VAS)</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Left Arm Pain Visual Analog Scale (VAS) data was available for 75 non-randomized SECURE-C, 133 randomized SECURE-C patients and 108 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Arm Pain Visual Analog Scale (VAS)</title>
          <description>Improvement of 20mm from baseline in left arm pain measured using the Visual Analog Scale (VAS)</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Left Arm Pain Visual Analog Scale (VAS) data was available for 75 non-randomized SECURE-C, 133 randomized SECURE-C patients and 108 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Arm Pain Visual Analog Scale (VAS)</title>
        <description>Improvement of 20mm from baseline in right arm pain measured using the Visual Analog Scale (VAS)</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Right Arm Pain Visual Analog Scale (VAS) data was available for 75 non-randomized SECURE-C patients, 133 randomized SECURE-C patients and 108 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc.</description>
          </group>
        </group_list>
        <measure>
          <title>Right Arm Pain Visual Analog Scale (VAS)</title>
          <description>Improvement of 20mm from baseline in right arm pain measured using the Visual Analog Scale (VAS)</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Right Arm Pain Visual Analog Scale (VAS) data was available for 75 non-randomized SECURE-C patients, 133 randomized SECURE-C patients and 108 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 PCS</title>
        <description>Health Status Survey SF-36 physical composite scores: 15% improvement from baseline</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete SF-36 PCS data was available for 78 non-randomized SECURE-C patients, 138 randomized SECURE-C patients and 114 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 PCS</title>
          <description>Health Status Survey SF-36 physical composite scores: 15% improvement from baseline</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete SF-36 PCS data was available for 78 non-randomized SECURE-C patients, 138 randomized SECURE-C patients and 114 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 MCS</title>
        <description>Health Status Survey SF-36 mental composite scores: 15% improvement from baseline</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete SF-36 MCS data was available for 78 non-randomized SECURE-C patients, 138 randomized SECURE-C patients and 114 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 MCS</title>
          <description>Health Status Survey SF-36 mental composite scores: 15% improvement from baseline</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete SF-36 MCS data was available for 78 non-randomized SECURE-C patients, 138 randomized SECURE-C patients and 114 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction</title>
        <description>Patient satisfaction (definitely/mostly): proportion of patients</description>
        <time_frame>24 months</time_frame>
        <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Patient Satisfaction data was available for 78 non-randomized SECURE-C patients, 139 randomized SECURE-C patients and 115 control patients at 24 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized SECURE-C Cervical Artificial Disc</title>
            <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
          </group>
          <group group_id="O2">
            <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
            <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
          </group>
          <group group_id="O3">
            <title>Non-Randomized SECURE-C Cervical Artificial Disc</title>
            <description>The first five subjects enrolled at each center were non-randomized subjects receiving the SECURE-C Cervical Artificial Disc.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction</title>
          <description>Patient satisfaction (definitely/mostly): proportion of patients</description>
          <population>At the time of database lock, of the 380 patients enrolled in the PMA study, all had reached the 24 month post-operative visit. Complete Patient Satisfaction data was available for 78 non-randomized SECURE-C patients, 139 randomized SECURE-C patients and 115 control patients at 24 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>The analysis of safety was based on the as-treated cohort of 380 total patients (88 non-randomized SECURE-C patients, 148 randomized SECURE-C patients, and 144 ACDF patients). The control ACDF group includes 140 patients randomized to ACDF, 3 patients randomized to SECURE-C who received ACDF, and 1 patient from the non-randomized cohort who received ACDF. The Clinical Events Committee (CEC) classified each adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>SECURE-C Cervical Artificial Disc</title>
          <description>Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc</description>
        </group>
        <group group_id="E2">
          <title>ASSURE Cervical Plate and an Allograft Interbody Spacer</title>
          <description>Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal Tunnel Syndrome (CTS)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Back and/or Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Upper Extremities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Compressive Periph Neuro (Non-CTS)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery - Adjacent Level</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Surgery - Index Level</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Surgery - Lumbar Level</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Surgery - Other Cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Surgery - Thoracic Level</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>.5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome (CTS)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Back and/or Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Neck and Upper Extremities</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Neck and Upper Extremities with Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Neck with Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Upper Extremities</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - Upper Extremities with Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection - Superficial Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Compressive Peripheral Neuropathy (Non-CTS)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Dysesthesia - Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Dysesthesia - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Dysesthesia - Upper Extremities</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound Issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>To prevent premature disclosure of information, Investigators agree not to present, publish, or disclose study results or information about the Investigational Device without the express written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jacqueline Myer</name_or_title>
      <organization>Globus Medical</organization>
      <phone>610-930-1800</phone>
      <email>jmyer@globusmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

